Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BrightSpring Health Services (BTSG) Common Equity (2023 - 2025)

BrightSpring Health Services (BTSG) has disclosed Common Equity for 3 consecutive years, with $1.9 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 13.79% year-over-year to $1.9 billion, compared with a TTM value of $1.9 billion through Dec 2025, up 13.79%, and an annual FY2025 reading of $1.9 billion, up 13.79% over the prior year.
  • Common Equity was $1.9 billion for Q4 2025 at BrightSpring Health Services, up from $1.8 billion in the prior quarter.
  • Across five years, Common Equity topped out at $1.9 billion in Q4 2025 and bottomed at $585.4 million in Q4 2023.
  • Average Common Equity over 3 years is $1.4 billion, with a median of $1.6 billion recorded in 2024.
  • The sharpest move saw Common Equity soared 181.49% in 2024, then increased 7.6% in 2025.
  • Year by year, Common Equity stood at $585.4 million in 2023, then skyrocketed by 181.49% to $1.6 billion in 2024, then increased by 13.79% to $1.9 billion in 2025.
  • Business Quant data shows Common Equity for BTSG at $1.9 billion in Q4 2025, $1.8 billion in Q3 2025, and $1.7 billion in Q2 2025.